Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68203 | 0.85 | CA14 (0.37) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL78691 | 0.85 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL2579003 | 0.81 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL16280777 | 0.81 | CA14 (0.39) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL1253034 | 0.79 | CA14 (0.38) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL27176906 | 0.79 | CA14 (0.49) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL4918504 | 0.78 | CA14 (0.37) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL30792573 | 0.78 | CA14 (0.37) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| SCHEMBL3076946 | 0.78 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2SSTR4 | |
| Glycine SCHEMBL28774225 | 0.78 | GLRA1 (0.39) | CA14HDAC6HDAC1HDAC2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CA14 1872/4885HDAC6 562/4885HDAC1 325/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | CA14 2775/4885HDAC6 582/4885HDAC1 265/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CA14 1963/4885HDAC6 566/4885HDAC1 328/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | CA14 2551/4885HDAC6 610/4885HDAC1 257/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | CA14 2775/4885HDAC6 582/4885HDAC1 265/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CA14 2898/4885HDAC6 477/4885HDAC1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.